Naming In The News
Ash Access Technology's New Flagship Product Name Created by Strategic Name Development
February 7, 2007 – Minneapolis, MN — Zuragen™, a novel, injectable antimicrobial/antithrombotic therapy from Ash Access Technology, Inc. was named by Strategic Name Development, a brand name consultancy that develops product names, company names, taglines and conducts brand name research.
Zuragen™ is being developed for the prevention and treatment of catheter related bloodstream infection (CRBSI) in patients requiring the use of a central venous catheter. In pre-clinical studies, Zuragen™ has demonstrated significant and rapid broad-spectrum antimicrobial efficacy as well as the elimination of biofilm – a safe haven for bacteria. In addition, the company will be looking to show that Zuragen™ is non-inferior to heparin (today's de facto standard of care) in terms of providing patency for central venous catheters.
Ash Access Technology initiated patient enrollment for the AZEPTIC (Analysis of Zuragen's Efficacy in the Prevention and Treatment of Catheter Infections) trial in August of 2006. Enrollment is expected to be completed this year.
"Zuragen™ is an exciting technology that addresses a significant unmet medical need and has the potential to be used across a wide range of patient populations," said Bob Truitt, President of Ash Access Technology. "In working with Strategic Name Development, we were able to develop a name that both defines our product's unique attributes and captures the excitement of technological innovation."
"It is an honor to work with Ash Access Technology because of its heritage and its commitment to combat deadly infection," said William Lozito, President of Strategic Name Development. "We are thrilled with the outcome of a collaborative name development process that resulted in a mellifluous combination of the familiar Latin and Greek roots, Zur- for the azure blue color of the product, and Gen- for the pathogen eradication it performs."
About Ash Access Technology, Inc.
Ash Access Technology, Inc., founded in 2003, is an integrated specialty pharmaceutical / medical device company engaged in the development and commercialization of proprietary therapies and devices to prevent and treat complications related to vascular access. The company has an advanced portfolio of innovative products targeting catheter-related bloodstream infections (CRBSI), biofilm elimination and poor patency (blood flow) – the significant challenges associated with the use of vascular access devices. For more information about Zuragen™ and Ash Access Technology Inc., please visit www.ashaccess.com.
About Strategic Name Development, Inc.
Strategic Name Development, Inc., partners with companies to develop product names, company names, taglines and to conduct brand name research. The brand name consultancy combines the three forces of linguistics, creativity and target-market research to build brand names that are instantly recognizable, memorable and strategically sound. For more information about Strategic Name Development, please visit www.namedevelopment.com.